Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. [electronic resource]
Producer: 20100323Description: 976-83 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bone Neoplasms -- drug therapy
- Breast Neoplasms -- drug therapy
- Capecitabine
- Deoxycytidine -- administration & dosage
- Docetaxel
- Feasibility Studies
- Female
- Fluorouracil -- administration & dosage
- Humans
- In Situ Hybridization, Fluorescence
- International Agencies
- Liver Neoplasms -- drug therapy
- Middle Aged
- Neoplasm Staging
- Prognosis
- Receptor, ErbB-2 -- genetics
- Soft Tissue Neoplasms -- drug therapy
- Survival Rate
- Taxoids -- administration & dosage
- Trastuzumab
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.